immunotherapy
-
September 10, 2021
Novel immunotherapy shows robust response for multiple myeloma
Vanderbilt research found that a novel immunotherapy demonstrated robust effectiveness in treating relapsed or refractory multiple myeloma. -
August 12, 2021
Study identifies biomarker for breast cancer response to immunotherapy
A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research. -
August 5, 2021
Clinical trial to test immunotherapy for rectal cancer
A new clinical trial seeks to determine whether immunotherapy in combination with short-course radiation followed by surgical resection could be a curative treatment for locally advanced rectal cancer. -
July 1, 2021
Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma
A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients. -
March 25, 2021
Forty-three percent of melanoma patients have chronic complications from immunotherapies
Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology. -
August 20, 2020
A “torque” for tumor blood vessels
Vanderbilt scientists have discovered a new target for normalizing tumor blood vessels to improve cancer immunotherapies. -
February 27, 2020
Patient’s cancer treatment includes new immunotherapy
Dona Potter, 87, rode Harleys and drove 18-wheelers back when men dominated the open highways, and she is still defying expectations.